Evidence Hub

Thymol as a Potential Natural Antiemetic: Insights From In Vivo and In Silico Studies

Showkoth Akbor, Mehedi Hasan Bappi, Abdullah Al Shamsh Prottay, Farjanamul Haque, Nayem Mia, Tawhida Islam, Zainab M. Almarhoon, Eda Sönmez Gürer et al.

Food Science & Nutrition, 2025

1 citation

Abstract

ABSTRACT Nausea and vomiting are common and distressing responses to toxins, chemotherapy, and gastrointestinal disturbances. Although antiemetic medications are available, their adverse effects make safer substitutes necessary. In our study, Thymol (THY), a phenolic monoterpene from essential oils, was evaluated for its antiemetic potential using in vivo and in silico methods. In the in vivo study, emesis was induced in 2‐day‐old chicks by oral administration of copper sulfate pentahydrate (50 mg/kg). THY was administered orally at doses of 10, 20, and 40 mg/kg, alone or in combination with standard antiemetics ondansetron (ODN), domperidone (DPD), hyoscine butyl bromide (HYS), and promethazine hydrochloride (PRO). The 20 mg/kg dose (THY‐20) showed the highest efficacy, significantly ( p < 0.0001) reducing the number of retches (24.6 ± 2.7; 67.2% reduction) and increasing latency to first retch (52.6 ± 4.2 s; 77.18% increase) compared to the negative control (NC). The THY + ODN combination further enhanced effects (68.53% retch reduction). Molecular docking showed strong binding of THY to 5‐HT 3A (−6.4 kcal/mol), D 2 (−7.1 kcal/mol), M 3 (−6.2 kcal/mol), and H 1 (−7.1 kcal/mol) receptors, comparable to standard drugs. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling revealed THY's compliance with Lipinski's Rule, high gastrointestinal absorption, blood–brain barrier permeability, and low toxicity risk. The multi‐target binding profile and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free